Publications

The Oxtend TM-01 study: Debio 4126, ​a new 12-week octreotide formulation, provides maintenance of disease control in patients with acromegaly…

Debio 4126, a new 3-month octreotide formulation, provides sustained release of octreotide, as well as enhanced bioavailability and similar suppression…